Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Integrated Diagnostics Holdings PLC

Healthcare GB IDHC

0.532GBX
0.00(0%)

Last update at 2026-06-11T15:35:00Z

52 Week Range

0.300.83
LowHigh

Fundamentals

  • Previous Close 0.53
  • Market Cap35460.90M
  • Volume3310
  • P/E Ratio0.20
  • Dividend Yield-%
  • EBITDA2223.60M
  • Revenue TTM6764.59M
  • Revenue Per Share TTM11.58
  • Gross Profit TTM 2745.93M
  • Diluted EPS TTM0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 1439.60M 737.36M 853.65M 2232.32M 969.08M
Minority interest 69.06M 41.94M 14.53M -79.89700M 156.38M
Net income 1077.43M 510.30M 541.11M 1412.61M 594.01M
Selling general administrative 324.06M 256.07M 201.72M 198.88M 221.87M
Selling and marketing expenses 208.94M 145.32M 157.66M 117.91M 107.22M
Gross profit 2181.55M 1524.35M 1462.06M 2804.07M 1342.58M
Reconciled depreciation 482.80M 401.24M 317.34M 238.64M 185.36M
Ebit 1610.17M 879.04M 1171.45M 2262.06M 985.55M
Ebitda 2092.97M 1280.28M 1488.79M 2593.62M 1264.42M
Depreciation and amortization 482.80M 401.24M 317.34M 331.56M 278.88M
Non operating income net other - - - - -
Operating income 1214.35M 737.76M 1171.45M 2262.06M 985.55M
Other operating expenses 4505.39M 3384.74M 2720.68M 2938.00M 1628.59M
Interest expense 170.57M 141.69M 122.68M 98.00M 67.85M
Tax provision 431.22M 268.99M 327.06M 739.82M 359.60M
Interest income 144.68M 72.78M 95.37M 113.18M 53.12M
Net interest income -52.22300M -88.20400M -40.21500M -4.85100M -18.40700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 431.22M 268.99M 327.06M 739.82M 359.60M
Total revenue 5719.74M 4122.51M 3605.05M 5224.71M 2656.26M
Total operating expenses 967.21M 786.59M 577.70M 517.35M 314.90M
Cost of revenue 3538.19M 2598.16M 2142.98M 2420.65M 1313.69M
Total other income expense net 225.25M -0.40600M -317.80000M -29.73900M -16.46400M
Discontinued operations - - - - -
Net income from continuing ops 1008.37M 468.36M 526.58M 1492.51M 609.48M
Net income applicable to common shares - - - 1412.61M 594.01M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 7129.25M 5770.33M 5296.20M 6236.09M 4177.41M
Intangible assets 460.03M 422.93M 418.19M 402.45M 399.80M
Earning assets - - - - -
Other current assets 80.30M 42.19M - 469.73M 383.48M
Total liab 3629.75M 2669.54M 2849.22M 3441.73M 1751.04M
Total stockholder equity 2710.15M 2678.90M 2154.10M 2582.85M 2269.99M
Deferred long term liab - - - - -
Other current liab 1038.68M 679.82M 1172.57M 2015.88M 745.39M
Common stock 1039.12M 1072.50M 1072.50M 1072.50M 1072.50M
Capital stock 1039.12M 1072.50M 1072.50M 1072.50M 1072.50M
Retained earnings 1812.71M 1280.29M 783.08M 1550.98M 603.32M
Other liab - - - 371.27M 275.53M
Good will 1346.04M 1287.25M 1285.45M 1256.41M 1259.96M
Other assets - - - 6.76M 5.42M
Cash 1188.08M 674.25M 648.51M 891.45M 600.13M
Cash and equivalents - - - - -
Total current liabilities 2163.74M 1275.45M 1465.03M 2348.92M 1009.36M
Current deferred revenue - - - - -
Net debt 284.01M 504.95M -532.08600M -793.38500M -48.05500M
Short term debt 460.73M 220.38M 22.68M 21.72M 85.93M
Short long term debt 224.53M 43.68M 22.68M 21.72M 25.42M
Short long term debt total 1472.09M 1179.20M 116.43M 98.07M 552.08M
Other stockholder equity -141.67800M 326.11M 298.51M -40.63000M 594.17M
Property plant equipment - - - 1517.48M 1142.28M
Total current assets 3080.24M 1962.39M 1625.26M 3042.51M 1360.35M
Long term investments - - - - -
Net tangible assets - - - 923.98M 610.24M
Short term investments 563.99M 186.25M 167.40M 1458.72M 276.62M
Net receivables 930.31M 685.05M 395.22M 371.05M 363.77M
Long term debt 40.48M 67.47M 93.75M 76.34M 67.62M
Inventory 317.56M 374.65M 265.46M 222.61M 100.11M
Accounts payable 320.07M 271.74M 269.78M 311.32M 178.04M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -753.23400M - - -459.39400M
Additional paid in capital - - - - -
Common stock total equity - - - - 1072.50M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 18.06M 1458.72M 276.62M
Deferred long term asset charges - - - - -
Non current assets total 4049.01M 3807.93M 3670.94M 3193.58M 2817.06M
Capital lease obligations 1207.09M 1068.05M 1062.90M 760.67M 459.04M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -446.71400M -243.94200M 990.11M -1327.84400M -55.00900M
Change to liabilities - - - 351.80M 53.82M
Total cashflows from investing activities -446.71400M -243.94200M - -1327.84400M -124.26800M
Net borrowings 149.89M -5.28100M - -54.57600M -56.43400M
Total cash from financing activities -748.99700M -330.46100M -1617.68700M -647.14900M -563.53600M
Change to operating activities - - - 0.68M -1.86600M
Net income 1439.60M 737.36M 853.65M 2232.32M 969.08M
Change in cash 513.83M 25.74M -242.93900M 291.32M 191.24M
Begin period cash flow 674.25M 648.51M 891.45M 600.13M 408.89M
End period cash flow 1188.08M 674.25M 648.51M 891.45M 600.13M
Total cash from operating activities 1568.60M 543.66M 208.73M 2269.84M 882.51M
Issuance of capital stock - - - - -
Depreciation 482.80M 401.24M 317.34M 238.64M 185.36M
Other cashflows from investing activities 128.13M 73.19M - 111.37M 51.44M
Dividends paid 27.42M - 1411.75M 478.75M 450.74M
Change to inventory 76.76M -104.90900M -30.15900M -127.64300M -17.12100M
Change to account receivables -208.75800M -198.07800M - -106.45800M -140.56300M
Sale purchase of stock -374.35400M 0.00000M - - -
Other cashflows from financing activities -497.11600M -86.04800M -167.18900M -142.98500M -87.38300M
Change to netincome - - - 500.21M 208.87M
Capital expenditures 224.60M 325.93M 308.84M 263.74M 126.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -33.01500M -387.94000M -250.30300M 118.38M -105.72900M
Stock based compensation 4.68M -7.09300M -7.59400M -0.86600M -3.21300M
Other non cash items -325.45600M -199.89800M -704.36400M 4.85M 18.41M
Free cash flow 1344.01M 217.73M -100.10900M 2006.11M 756.50M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IDHC
Integrated Diagnostics Holdings PLC		 - -% 0.53 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 -0.35 4.02% 8.35 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 -0.909 7.21% 11.69 - 53.19 2.19 3.19 1.81 -0.2499
CLBX
CelLBxHealth plc		 -0.075 4.05% 1.77 - - 7.05 1.50 6.07 -1.6211
GDR
genedrive plc		 -0.05 4.08% 1.18 - 12.38 12.99 10.61 16.54 -6.0473

Reports Covered

Stock Research & News

View All

Profile

Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron emission tomography - computed tomography (PET-CT), MRI, computed tomography (CT), mammography, ultrasound, X-Ray, electromyography, electroencephalography, electroencephalogram, and electrocardiogram, as well as operates cath lab facilities. It operates in Egypt, Sudan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is based in Saint Helier, Jersey.

Integrated Diagnostics Holdings PLC

IFC 5, Saint Helier, Jersey, JE1 1ST

Key Executives

Name Title Year Born
Dr. Hend El Sherbini Group CEO & Exec. Director 1969
Mr. Omar Bedewy Group CFO and VP of Fin. & Strategies NA
Dr. Eissa Khorshid Chief Operating Officer NA
Nancy Fahmy Investor Relations Director NA
Mr. Mohamed Kamel Saleh Gen. Counsel 1982
Dr. Seham Ibrahim Sales Director 1969
Dr. Moushira El Saifi Head of Hematology Department NA
Dr. Mohamed Akram Abdel-Rahman Nouh Head of Pathology Department and Information Technology Administrator NA
Dr. Osama S. Zaghloul Managing Director of Ultralab 1960
Dr. Amid Abdelnour Managing Director of Biolab 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions